Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innate Pursues Anti-Leukemic In EU

Lumoxiti Potentially Transformative For French Firm

Executive Summary

Innate Pharma pursues refractory hairy cell leukemia opportunity with first-in-class CD22-directed immunotoxin, moxetumomab pasudotox-tdfk.

You may also be interested in...



AstraZeneca And Galapagos Shine At The 15th Annual Scrip Awards

The pharma, biotech and allied industries came together in London on 4 December to celebrate another year of achievement at the 15th Annual Scrip Awards, hosted by the broadcaster Fiona Bruce.

Ten Strategies For Success In Antibody-Drug Conjugate Development

The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a slice of the growing opportunity?

Celgene pays $450m for AZ's MEDI4736 in blood cancers; AZ signs $250m+ Innate deal

Celgene is paying AstraZeneca $450m up front in order to develop the UK drug maker's anti-PD-L1 product MEDI4736 in a range of blood cancers – a partnership Celgene thinks could be a "meaningful" driver of growth past 2020.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel